63121-00-6

63121-00-6 structure

Name: Oxaliplatin
Chemical Name: Platinum(2+) ethanedioate-1,2-cyclohexanediamine (1:1:1)
CAS Number: 63121-00-6
Molecular Formula: C₈H₁₄N₂O₄Pt
Molecular Weight: 397.292
Catalog: API Antineoplastic agents Other antineoplastic agents
Create Date: 2018-06-20 17:21:30
Modify Date: 2024-01-02 18:47:31
(rel)-Oxaliplatin is a DNA synthesis inhibitor. (rel)-Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. (rel)-Oxaliplatin can be used for cancer research[1][2][3].

Name	Platinum(2+) ethanedioate-1,2-cyclohexanediamine (1:1:1)
Synonyms	Oxaliplatin platinum, [ethanedioato(2-)-κO,κO]-, compd. with (1R,2R)-1,2-cyclohexanediamine (1:1) Platinum(2+) ethanedioate - (1R,2R)-1,2-cyclohexanediamine (1:1) Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1) [Ethanedioato(2-)-κO,O]platinum - (1R,2R)-cyclohexane-1,2-diamine (1:1) Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1)

Description	(rel)-Oxaliplatin is a DNA synthesis inhibitor. (rel)-Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. (rel)-Oxaliplatin can be used for cancer research[1][2][3].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Cell Cycle/DNA Damage >> DNA/RNA Synthesis
In Vitro	(rel)-Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis[1]. (rel)-Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)[2]. (rel)-Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively[3] Cell Viability Assay[1] Cell Line: HCC, HCCLM3 and Hep3B cells Concentration: 24, 48 and 72 hours Incubation Time: 2, 4, 8, 16, 32, 64 and 128 μM Result: Decreased cell viability in a dose- and time-dependent manner. Western Blot Analysis[1] Cell Line: HCCLM3 and Hep3B cells Concentration: 48 hours Incubation Time: 10 μM Result: Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax. Cell Cycle Analysis[1] Cell Line: HCCLM3 and Hep3B cells Concentration: 24 hours Incubation Time: 10 μM Result: Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).
In Vivo	(rel)-Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth[1]. Animal Model: Nude mice[1] Dosage: 5 and 10 mg/kg Administration: Intraperitoneal injection; for 32 days Result: Reduced tumor volume in HCCLM3 tumor xenografts.
References	[1]. Woynarowski JM, et, al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol. 2000 Nov;58(5):920-7. [2]. Wang Z, et, al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604. [3]. Pendyala L, et, al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6.

Boiling Point	193.6ºC at 760 mmHg
Molecular Formula	C₈H₁₄N₂O₄Pt
Molecular Weight	397.292
Flash Point	75ºC
Exact Mass	397.060150
PSA	132.30000
Storage condition	-20°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: TP2280000

CHEMICAL NAME :: Platinum (II), (cyclohexane-1,2-diammine)oxalato-

CAS REGISTRY NUMBER :: 63121-00-6

LAST UPDATED :: 199706

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C8-H14-N2-O4-Pt

MOLECULAR WEIGHT :: 397.33

WISWESSER LINE NOTATION :: L6TJ AZ BZ &QVVQ &-PT-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 19800 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: RIYADS Rinsho Yakuri. Clinical Pharmacology. (Nippon Rinsho Yakuri Gakkai, c/o Tokyo Ika Shika Daigaku Nanchi Shikkan Kenkyusho, 2-3-10 Suragadai, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1970- Volume(issue)/page/year: 16,147,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 30 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ. Volume(issue)/page/year: 61,1519,1977

61825-94-3	63121-00-6
61758-77-8	111321-67-6
56270-79-2	930113-49-8